Effect of Baseline Symptom Manifestations on Retention in Care and Treatment among HIV-Infected Patients in Nigeria
Juliet Adeola, MS, BSc1,2 , Okikiolu Abimbola Badejo, MBChB, MPH1,3, Aimalohi Ahonkhai, MD, MPH4, Prosper Okonkwo, MBBS, FWACP, FMCPH1, Patrick Aboh Akande, MBBS, MPH, DrPH1, Charlesnika Tyon Evans, PHD, MPH2, Megan McHugh, PHD2, Leslie Pierce, MPH4, Isah Ahmed, HND, PGD1, Toyin Jolayemi, MBBS1, Babatunde Ladi Akinyemi, M.B.CH.B, MPH, FWACS1, Ifeyinwa Onwuatuelo, DDS, MPH1, Robert Murphy, MD2, Demetrious Kyriacou, MD, PHD2, Jonah Musa, MD, PHD5, and Patricia Agaba, MBBS, MPH5
Epidemiologic and viral predictors of antiretroviral drug resistance among persons living with HIV in a large treatment program in Nigeria
Ernest Ekong1,2*†^, Nicaise Ndembi1,2*† , Prosper Okonkwo3, Patrick Dakum1,2, John Idoko4, Bolanle Banigbe3, James Okuma1, Patricia Agaba4, William Blattner2, Clement Adebamowo2 and Manhattan Charurat2
Epidemiologic and viral predictors of antiretroviral drug resistance among persons living with HIV in a large treatment program in Nigeria
Ernest Ekong1,2*†^, Nicaise Ndembi1,2*† , Prosper Okonkwo3, Patrick Dakum1,2, John Idoko4, Bolanle Banigbe3, James Okuma1, Patricia Agaba4, William Blattner2, Clement Adebamowo2 and Manhattan Charurat2
Opportunities and challenges to integrating mental health into HIV programs in a lowand middle-income country: insights from the Nigeria implementation science Alliance
Echezona E. Ezeanolue1,2, Theddeus Iheanacho3* , Isaac A. Adedeji4, Ijeoma Uchenna Itanyi1,5, Babayemi Olakunde1,6, Dina Patel2, Patrick Dakum7,8, Prosper Okonkwo9, Timothy Akinmurele10, Michael Obiefune11, Hadiza Khamofu12, Bolanle Oyeledun13, Muyiwa Aina14, Andy Eyo15, Obinna Oleribe16, John Oko17, Ayodotun Olutola18, Ibrahim Gobir19, Muktar H. Aliyu20, Gambo Aliyu6, Godfrey Woelk21, Gregory Aarons22, George Siberry23, Rachel Sturke24 and Nigeria Implementation Science Alliance25
The impact of HIV-1 subtypes on virologic and immunologic treatment outcomes at the Lagos University Teaching Hospital: A longitudinal evaluation
Ann Abiola OgbennaID 1☯*, Seema Meloni2☯, Seth Inzaule3, Raph L. Hamers3,4,5, Kim Sigaloff3,6, Akin Osibogun7, Titilope Adenike Adeyemo1, Prosper Okonkwo8, Jay Osi Samuels8, Phyllis J. Kanki2, Tobias F. Rinke de Wit3, Alani Sulaimon Akanmu1☯ 1
Effect of PEPFAR funding policy change on HIV service delivery in a large HIV care and treatment network in Nigeria
Bolanle Banigbe1, Carolyn M. Audet2,3,4, Prosper Okonkwo1, Olujide O. Arije5, Elizabeth Bassi1, Kate Clouse2,6, Melynda Simmons2, Muktar H. Aliyu2,3, Kenneth A. Freedberg7,8,9,10,11, Aima A. AhonkhaiID 2,6,7,8,9*
Safety and efficacy of rifabutin among HIV/TB-coinfected children on lopinavir/ritonavir-based ART
Holly E. Rawizza1,2*, Kristin M. Darin3, Regina Oladokun4, Biobele Brown4, Babatunde Ogunbosi4, Nkiruka David5, Sulaimon Akanmu6, Oluremi Olaitan7, Charlotte Chang2, Kimberly K. Scarsi8, Prosper Okonkwo7 and Phyllis J. Kanki2
High Medication Possession Ratios Associated with Greater Risk of Virologic Failure Among Youth Compared to Adults in a Nigerian Cohort
Aimalohi A. Ahonkhai, MD, MPH1,2,3,4,5,+,§, Bolanle Banigbe, MD, MPH6, Juliet Adeola, BSc, MBA6, Ingrid V. Bassett, MD, MPH3,4,5,7, Ifeoma Idigbe, M.Sc8, Prosper Okonkwo, MD, FMCPH6, Kenneth A. Freedberg, MD, MSc33,4,5,7,9,10, Susan Regan, PhD4,7,10, and Elena Losina, PhD4,5,11,12
Safety and efficacy of rifabutin among HIV/TB-coinfected children on lopinavir/ritonavir-based ART
Holly E. Rawizza1,2*, Kristin M. Darin3, Regina Oladokun4, Biobele Brown4, Babatunde Ogunbosi4, Nkiruka David5, Sulaimon Akanmu6, Oluremi Olaitan7, Charlotte Chang2, Kimberly K. Scarsi8, Prosper Okonkwo7 and Phyllis J. Kanki2
Treatment Outcomes Among Older Human Immunodeficiency Virus-Infected Adults in Nigeria
Patricia A. Agaba, Seema T. Meloni, Halima M. Sule, Oche O. Agbaji, Atiene S. Sagay, Prosper Okonkwo, John A. Idoko, and Phyllis J. Kanki